Artis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company, has agreed to acquire Syngoi Technologies, a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies.

The acquisition will advance Artis’ strategy of building a differentiated platform to accelerate gene-to-drug discovery across a range of therapeutic modalities by adding fast and cost-effective enzymatic-based synthetic DNA manufacturing capabilities.

Following closing, Artis will establish a U.S. operating presence for Syngoi’s technology through its wholly-owned entity, Landmark Bio, positioning Artis as one of the first platforms to combine GMP synthetic DNA manufacturing with integrated advanced-therapy capabilities in the United States. Together, Artis, Landmark Bio, and Syngoi aim to expand the scope of solutions available to advanced-therapy developers in the U.S., Europe, and globally, enabling greater flexibility in how critical inputs and manufacturing pathways are brought together.

Syngoi’s European GMP-ready facilities in Bilbao will become a central component of Artis’ global footprint. Artis will also continue to invest in Syngoi’s operations and team in Bizkaia. The Bizkaia site will serve as a key reference center underpinning Artis’s differentiated global vision in Advanced Therapies.

“This acquisition enables customers to reduce fragmentation and inefficiency in gene-to-drug development by introducing innovative synthetic DNA manufacturing solutions,” said Brian Neel, Co-Founder & CEO, Artis BioSolutions. “By combining Syngoi Technologies and Landmark Bio, we expand our ability to support advanced-therapy programs from early development through clinical manufacturing, while continuing to invest in the teams and regions driving innovation.”

“Joining Artis marks an important next chapter for Syngoi,” said José Vicente Pons Andreu, Chief Executive Officer, Syngoi. “Artis shares our long-term vision, and together with Landmark Bio, this partnership significantly enhances our ability to deliver differentiated synthetic DNA solutions at a global scale. It strengthens our value proposition for customers and partners seeking reliable, high-quality platforms for advanced therapies.”

The transaction is expected to close in Q1 2026, subject to customary regulatory approvals and closing conditions. Financial terms were not disclosed.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.